Skip to search formSkip to main contentSkip to account menu

Bortezomib-Dexamethasone Regimen

Known as: Velcade-Dexamethasone Regimen 
A regimen consisting of bortezomib and dexamethasone used as treatment for relapsed or refractory multiple myeloma.
National Institutes of Health

Related topics

Related topics

3 relations
DexamethasoneMultiple Myelomabortezomib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction…
Introduction: Multiple Myeloma (MM) is an incurable disease. In young patients, autologous bone marrow transplantation (ABMT… 
2016
2016
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
Light chain deposition disease (LCDD) is a rare plasma cell dyscrasia consisting of nonamyloidotic deposition of misfolded… 
2013
2013
Mr-016. Phase Ii Pilot Study Of Velcade® (bortezomib) In Combination With Temozolomide And Regional Radiation Therapy For Upfront Treatment Of Patients With Newly-diagnosed Glioblastoma Multiforme
PURPOSE: To assess interim safety and tolerability of 12 patients in a phase II pilot study using Bortezomib in combination with… 
2009
2009
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines
PurposeProteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study… 
2008
2008
Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).
NF-κB is deregulated in several lymphoma subtypes, including aggressive B-NHL and T-NHL. The proteasome inhibitor, bortezomib… 
2007
2007
Charakterisierung der potentiellen Lebertoxizität und tumorspezifischen Apoptoseinduktion durch eine kombinierte TRAIL/Bortezomib-Behandlung gastrointestinaler Tumore
Als Mitglied der TNF-Superfamilie induziert TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) Apoptose in… 
2006
2006
Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.
The mechanisms by which Bortezomib elicits its antitumor activity may vary among tumor types, and the extent to which each… 
2006
2006
Safety and Efficacy of Bortezomib (VELCADE™) in 104 Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy: Impact of Cytogenetics on…
Background: Bortezomib (VELCADE™) is a reversible proteasome inhibitor that has been shown to be safe and efficacious in patients… 
2004
2004
Bortezomib (Velcade®) - ein neues Wirkungsprinzip in der Behandlung des multiplen Myeloms
Das multiple Myelom (MM) ist eine Erkrankung der Plasmazellen und gehört zu den lymphoproliferativen Erkrankungen der B… 
2004
2004
Velcade® (bortezomib) dans le traitement du myélome multiple : résultats des essais cliniques
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)